Obiltoxaximab

Drug Profile

Obiltoxaximab

Alternative Names: Anthim; ETI-204

Latest Information Update: 19 Sep 2016

Price : $50

At a glance

  • Originator Elusys Therapeutics
  • Class Antibacterials; Antitoxins; Monoclonal antibodies
  • Mechanism of Action Anthrax toxin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Anthrax
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Anthrax

Most Recent Events

  • 14 Sep 2016 Adverse events data and pharmacokinetics data in Healthy volunteers released by Elusys Therapeutics
  • 20 Jul 2016 Efficacy data from a preclinical trial in Anthrax released by Elusys Therapeutics (3193287; 9199843)
  • 19 Apr 2016 Efficacy data from a preclinical trial in Anthrax released by Elusys Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top